• Hiroo Imura
  • Yuzuru Kato
  • Naoki Hattori
Part of the Serono Symposia, USA book series (SERONOSYMP)


A unique disfigurement of acromegaly was seen in ancient paintings or statues, but the association of pituitary enlargement with this disease was first noted by Pierre Marie. Its association with growth hormone (GH) hypersecretion was suggested by Cushing and later confirmed by bioassay and radioimmunoassay (RIA). Since then, RIA has been extensively used in the diagnosis and evaluation of treatment of acromegaly.


Growth Hormone Pituitary Adenoma Vasoactive Intestinal Polypeptide Acromegalic Patient Luteinizing Hormone Release Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beck C, Larkins RG, Martin TJ, et al. Stimulation of growth hormone release from superfused rat pituitary by extracts of hypothalamus and of human lung tumours. J Endocrinol 1973; 59: 325–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Asa SL, Scheithauer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 1984; 58: 796–803.PubMedCrossRefGoogle Scholar
  3. 3.
    Scheithauer BW, Kovacs K, Randall RV, et al. Pathology of excessive production of growth hormone. Clin Endocrinol Metab 1986; 15: 665–81.CrossRefGoogle Scholar
  4. 4.
    1980 Annual Report of Study Group on Hypothalamopituitary Diseases supported by Ministry of Health and Welfare, 1980:15–24.Google Scholar
  5. 5.
    Imura H, Kato Y, Ishikawa E. Growth hormone secretion in acromegaly. In: Robbins R, Melmed S, eds. Acromegaly: a century of scientific and clinical progress. New York: Plenum Press, 1987: 83–95.Google Scholar
  6. 6.
    Kashio Y, Chihara K, Kaji H, et al. Presence of growth hormone- releasing factor-like immunoreactivity in human cerebrospinal fluid. J Clin Endocrinol Metab 1985; 60: 396–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Matsushita N, Kato Y, Katakami H, et al. Stimulation of growth hormone release by vasoactive intestinal polypeptide from human pituitary adenoma in vitro. J Clin Endocrinol Metab 1981; 53: 1297–300.PubMedCrossRefGoogle Scholar
  8. 8.
    Ishibashi M, Yamaji T. Direct effects of catecholamines, thyrotropin-releasing hormone and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pitu¬itary cells in culture. J Clin Invest 1984; 73: 66–78.PubMedCrossRefGoogle Scholar
  9. 9.
    Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301: 1138–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Hattori N, Kato Y, Murakami Y, et al. Measurement of urine human growth hormone levels by ultra-highly sensitive enzyme immunoassay. Folia Endocrinol Jpn (in press).Google Scholar
  11. 11.
    Hashida S, Ishikawa E, Nakagawa K, et al. Demonstration of human growth hormone in normal urine by a highly specific and sensitive sandwich enzyme immunoassay. Anal Lett 1985; 18: 1623–34CrossRefGoogle Scholar
  12. 12.
    Hashida S, Nakagawa K, Ishikawa E, et al. Basal level of human growth hormone (hGH) in normal serum. Clin Chim Acta 1985; 151: 185–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Grossman A, Ross R, Wass JAH, et al. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol 1986; 24: 231–8.CrossRefGoogle Scholar
  14. 14.
    Ishibashi M, Fukushima I, Yamaji T. Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture. Acta Endocrinol (Copenh) 1985; 109: 474–80.Google Scholar
  15. 15.
    Lamberts SWJ, Uilterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313: 1576–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Tolis G, Yotis A, del Pozo E, et al. Therapeutic efficacy of somatostatin analogue (SMS 201-995) in active acromegaly. J Neurosurg 1986; 65: 37–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Barnard LB, Grantham WG, Lamberton P, et al. Treatment of resistant acromegaly with a long-acting somatostatin. Ann Intern Med 1986; 105: 856–61.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Hiroo Imura
    • 1
  • Yuzuru Kato
    • 2
  • Naoki Hattori
    • 1
  1. 1.Department of Medicine, KyotoUniversity Faculty of MedicineSakyo-ku, KyotoJapan
  2. 2.Department of MedicineShimane Medical UniversityIzumo, ShimaneJapan

Personalised recommendations